| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 09/12/2003 | CA2477794A1 System and method for the production of recombinant glycosylated proteins in a prokaryotic host |
| 09/12/2003 | CA2477662A1 Genes involved in regulating angiogenesis, pharmaceutical preparations containing same and applications thereof |
| 09/12/2003 | CA2477647A1 Dna vaccines encoding cea and a cd40 ligand and methods of use thereof |
| 09/12/2003 | CA2477411A1 Local production and/or delivery of anti-cancer agents by stromal cell precursors |
| 09/12/2003 | CA2477312A1 Use of soluble fgl2 as an immunosuppressant |
| 09/12/2003 | CA2477075A1 Pharmaceutical and cosmetic compositions comprising plgf-1 |
| 09/12/2003 | CA2476724A1 Prevention of recurrence and metastasis of cancer |
| 09/12/2003 | CA2476410A1 Methods to increase or decrease bone density |
| 09/12/2003 | CA2475370A1 Conjugates of the c domain of human gelatinase a and polyethylene glycol, methods of purification and uses thereof |
| 09/12/2003 | CA2456077A1 Individualized anti-cancer antibodies |
| 09/12/2003 | CA2455447A1 Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina) |
| 09/11/2003 | WO2003074129A1 Compositions and methods for treatment of body weight conditions with milk minerals and casein fractions |
| 09/11/2003 | WO2003074075A1 Pharmaceutical and cosmetic compositions comprising plgf-1 |
| 09/11/2003 | US20030172407 Method of producing single chain protein in plant cells |
| 09/11/2003 | US20030172389 Surfactant protein D for the prevention and diagnosis of pulmonary emphysema |
| 09/11/2003 | US20030172388 Methods and compositions relating to fortilin, an anti-apoptotic molecule, and modulators of fortilin |
| 09/11/2003 | US20030171773 Methods for aneurysm repair |
| 09/11/2003 | US20030171569 A genetic engineered DNA molecule, probes, vectors, gene expression is inhibited by a growth hormone, for treating tumor; antitumor agents |
| 09/11/2003 | US20030171568 Diagnosing tumor or cancer in a mammal, and inflammatory diseases or disorders; inflammatory bowel disease, colon cancer; immunoassay, immunotherapy |
| 09/11/2003 | US20030171567 Recombinant allergen, fragments thereof, corresponding recombinant DNA molecules, vectors and hosts containing the DNA molecules, diagnostic and therapeutic uses of said allergens and fragments |
| 09/11/2003 | US20030171566 An isolated human nucleic acid encoding a nevoid basal cell carcinoma syndrome protein, antibodies, detecting tumor protein, therapeutic treatment of tumor, cancer; genetic engineering |
| 09/11/2003 | US20030171564 Novel argS |
| 09/11/2003 | US20030171559 A colony-stimulating factor hybrid molecules, computer analyzing the three dimensional structure protein, crystallization of the protein |
| 09/11/2003 | US20030171556 Diagnosis and therapeutic treatment of Alzheimer's Disease; drug screening |
| 09/11/2003 | US20030171555 Antitumor agents |
| 09/11/2003 | US20030171554 Tumour necrosis factor peptide binding antibodies |
| 09/11/2003 | US20030171553 Tumour necrosis factor binding ligands |
| 09/11/2003 | US20030171552 A single-chain T-cell receptor covalently linked to single-chain antibody; anticarcinogenic agents for treating cancer |
| 09/11/2003 | US20030171551 Chimeric antibody fusion proteins for the recruitment and stimulation of an antitumor immune response |
| 09/11/2003 | US20030171550 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 09/11/2003 | US20030171547 Adipocyte-specific protein homologs |
| 09/11/2003 | US20030171546 Chimeric immunoreceptor useful in treating human cancers |
| 09/11/2003 | US20030171542 Mammalian secretory peptide - 9 |
| 09/11/2003 | US20030171541 Selective binding agents, vectors, host cells, and methods for producing GPCR polypeptides; diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with GPCR polypeptides |
| 09/11/2003 | US20030171539 Synthetic oligopeptide heparin-neutralizing agents including basic amino acids and a N-heterocyclic end group; low turbidity; side effects reduction; in vitro diagnosis; calculate the blood clotting time; assaying clotting cascade |
| 09/11/2003 | US20030171537 Peptides and peptidomimetics with structural similarity to human p53 that activate p53 function |
| 09/11/2003 | US20030171536 Solid phase synthesis by the condensation of three partial fragments being carried out between the amino acid positions Glycine 108 and Arg 109 and amino acid positions Gly 120 and Cys 121; cyclization; deblocking; side-effects reduction |
| 09/11/2003 | US20030171365 Inhibitors of the interleukin-1beta conversion enzyme; useful in treatment of inflammatory, auto-immune and neurodegenerative diseases |
| 09/11/2003 | US20030171335 Antisense antiviral agent and method for treating ssRNA viral infection |
| 09/11/2003 | US20030171334 Treatment of prostate cancer |
| 09/11/2003 | US20030171328 Non-invasive method for detecting target-RNA |
| 09/11/2003 | US20030171326 Methods and compositions for modulating telomerase reverse transcriptase (TERT) expression |
| 09/11/2003 | US20030171324 Reagents which bind to human DESC1-like serine protease gene products can play a role in preventing, ameliorating, or correcting dysfunctions or diseases including, but not limited to cancer, chronic obstructive pulmonary disease (COPD), |
| 09/11/2003 | US20030171321 Immunostimulatory oligodeoxynucleotides |
| 09/11/2003 | US20030171319 Human chemokine beta-10 mutant polypeptides |
| 09/11/2003 | US20030171318 Methods for inhibiting virus propagation and treating virus infection are provided which include administering to cells infected with viruses a compound capable of inhibiting viral budding from the cells. |
| 09/11/2003 | US20030171317 Methods and compositions for reducing bacterial tolerance to antibacterials, disinfectants and organic solvents |
| 09/11/2003 | US20030171314 Early protection of susceptible animals against foot and mouth disease (FMD) may be achieved by inoculating the animals with a vaccine comprising an interferon DNA sequence. One day after inoculation, animals have been found protected from |
| 09/11/2003 | US20030171313 Antisense oligonucleotides are provided which are complementary to and hybridizable with at least a portion of HCV RNA and which are capable of inhibiting the function of the HCV RNA. These oligonucleotides can be administered to |
| 09/11/2003 | US20030171312 Dystrophin minigenes that retain the essential biological functions. The expression of the dystrophin minigenes may be controlled by a regulatory element along with a small polyadenylation signal. The entire gene expression cassettes |
| 09/11/2003 | US20030171311 Compounds, including enzymatic nucleic acid molecules, ribozymes, DNAzymes, nuclease activating compounds and chimeras such as 2',5'-adenylates, that modulate the expression and/or replication of hepatitis C virus |
| 09/11/2003 | US20030171310 Modulating the expression of RECQL. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding RECQL. Methods of using these compounds for modulation of RECQL expression and for |
| 09/11/2003 | US20030171304 Pyridine-2-yl-aminoalkyl carbonyl glycyl-$g(b)-alanine and derivatives thereof |
| 09/11/2003 | US20030171300 Treating different types and symptoms of acute and chronic pain, especially non neuropathic inflammatory pain in mammals. The pain to be treated may be e.g. chronic inflammatory pain, rheumatoid arthritis pain and/or secondary |
| 09/11/2003 | US20030171299 Stable, biologically compatible pharmaceutical compositions in the form of water-in-oil microemulsions (w/o), for the sustained release by parenteral administration of active ingredients which are hydrophilic or are made hydrophilic by |
| 09/11/2003 | US20030171298 Retroinverso polypeptides that mimic or inhibit thrombospondin |
| 09/11/2003 | US20030171297 A compound comprising tie amino acid sequence AMVSE, wherein said compound does not compromise the amino acid sequence EQEYVQTV The compound is useful as an anti-inflammatory agent. |
| 09/11/2003 | US20030171296 Pharmaceutical formulations for sustained drug delivery |
| 09/11/2003 | US20030171295 Drug screening assays, and diagnostic and therapeutic methods for the treatment of body weight disorders, such as obesity, anorexia and cachexia, utilizing the melanocortin 4-receptor (MC4-R) as the target for intervention |
| 09/11/2003 | US20030171294 Unit angiogenic agent, typically from 5 ng to 67,500 ng. Preferably, the angiogenic agent is FGF, more preferably it is basic FGF, Inducing angiogenesis or myocardial perfusion or vascular density into a heart |
| 09/11/2003 | US20030171293 Identification of an orphan G- protein coupled receptor MRGX2 (and variants thereof) as a receptor of neuropeptides such as but not limited to cortistatin, somatostatin, Bam 13-22, alpha -MSH, neuropeptide FF, dynorphin A and substance P, and the |
| 09/11/2003 | US20030171292 Method for using lipoprotein associated coagulation inhibitor to treat sepsis |
| 09/11/2003 | US20030171290 Methods to determine peptides presented on the surface of mammalian cells following addition to the cells of a protein. The present invention also relates to diagnostic tests based on the determination of such peptides or modified molecules |
| 09/11/2003 | US20030171289 Peptides blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis, polynucleotides encoding said peptides and methods of use thereof |
| 09/11/2003 | US20030171288 Methods for the prevention and treatment of a variety of mammalian conditions manifested by loss of bone mass, including osteoporosis. The present invention provides methods of using PTHrP, or analogs thereof, for the treatment of |
| 09/11/2003 | US20030171287 Medicinal compositions for angiogenic therapy |
| 09/11/2003 | US20030171283 Inhibin compositions and methods of enhancing production performance |
| 09/11/2003 | US20030171282 Systemic delivery of parathyroid hormone to a mammalian host is accomplished by inhalation through the mouth of a dispersion of an N-terminal fragment of PTH. It has been found that such respiratory delivery of the PTH fragment |
| 09/11/2003 | US20030171281 Therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, in the treatment of microorganism-caused infections, which infections may be systemic, such as a |
| 09/11/2003 | US20030171280 Compositions and methods for modulation of immune responses |
| 09/11/2003 | US20030171279 Methods and composition concerning herpesvirus Us3 and BAD-involved apoptosis |
| 09/11/2003 | US20030171278 Novel compounds which bind to the human erbB2 gene product (ErbB2, also known as HER2, or c-ErbB-2). In particular aspects, the invention provides for the treatment of disorders characterized by the overexpression of ErbB2 utilizing the |
| 09/11/2003 | US20030171277 Orally administered peptides to ameliorate atherosclerosis |
| 09/11/2003 | US20030171276 Capable of inhibiting the binding of hepatitis virus and a target cell, thereby preventing or treating chronic hepatitis; and a fusion interferon capable of still more improving a viral clearance ratio at the termination of |
| 09/11/2003 | US20030171275 Transporters and ion channels |
| 09/11/2003 | US20030171274 Antimicrobial proteins |
| 09/11/2003 | US20030171273 DNA of SEQ ID NO:1 is provided that encodes the transcription factor BP1, which is believed to be a repressor of the beta -globin gene. A host cell that is transformed with a vector that contains the DNA may be used to produce BP1. |
| 09/11/2003 | US20030171272 Cystatin superfamily includes inhibitors of cysteine proteinases, which function in a protective role with regard to various pathological actions of endogenous proteinases. Zcys7 is a new member of this superfamily. |
| 09/11/2003 | US20030171271 Therapeutic application in the treatment of conditions including cancer, macular degeneration and retinopathies. Also included are methods of treating a patient having a pathological condition characterized by an increase in |
| 09/11/2003 | US20030171269 Novel epidermal growth factor protein and gene, and methods of use therefor |
| 09/11/2003 | US20030171268 polynucleotides which identify and encode HuLEAP. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HuLEAP and a method for producing HuLEAP. |
| 09/11/2003 | US20030171267 Albumin fusion proteins |
| 09/11/2003 | US20030171266 Frameshift mutants of beta-amyloid precursor protein and ubiquitin-b and their use |
| 09/11/2003 | US20030171265 Method of treating conditions associated with intestinal ischemia/reperfusion |
| 09/11/2003 | US20030171264 Microemulsion preconcentrate; reduced toxicity but high bioavailability; contain cyclosporin A analog ISATx247 (Voclosporin), tocopheryl polyethylene glycol 1000 succinate (Vitamin E TPGS), medium chain triglyceride (MCT) oil, a Tween" emulsifier, and ethanol |
| 09/11/2003 | US20030171263 Methods for treating transplant rejection |
| 09/11/2003 | US20030171259 Method for administering insulin to the buccal region |
| 09/11/2003 | US20030171256 Enzymatic treatment of whey proteins for the production of antihypertensive peptides, the resulting products and treatment of hypertension in mammals |
| 09/11/2003 | US20030171253 Methods and compositions relating to modulation of A20 |
| 09/11/2003 | US20030171252 Nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for human |
| 09/11/2003 | US20030170893 Nanocapsule encapsulation system and method |
| 09/11/2003 | US20030170891 RNA interference mediated inhibition of epidermal growth factor receptor gene expression using short interfering nucleic acid (siNA) |
| 09/11/2003 | US20030170885 Used for the transfer and expression of exogenous nucleotide sequences in a host cell or organism; gene therapy |
| 09/11/2003 | US20030170866 Novel cyclin-selective ubiquitin carrier polypeptides |
| 09/11/2003 | US20030170865 Novel polypeptide of protein p140 and DNAs encoding it |
| 09/11/2003 | US20030170863 Prevents side effects such as systemic activation of coagulation system, bleeding |
| 09/11/2003 | US20030170862 Nuclear factor kappaB inducing factor |
| 09/11/2003 | US20030170860 Polynucleotide encoding a polypeptide having heparanase activity and expression of same in genetically modified cells |
| 09/11/2003 | US20030170859 Gene expression inhibition; for treatment of inflammatory, neurological, cardiovascular, and neoplastic tisssue growth disorders |
| 09/11/2003 | US20030170856 Regulation of human map kinase phosphatase-like enzyme |